Avenda Health Company Research Report

Company Overview

• Name: Avenda Health

• Mission: Creating a more personalized future of prostate cancer care.

• Founded: No information is available.

• Founders:

• Shyam Natarajan, PhD (Founder/CEO)

• Brit Berry-Pusey, PhD (Founder/COO)

• Leonard S. Marks, MD (Founder/CMO)

• Key People in the Company:

• Shyam Natarajan, PhD (CEO)

• Brit Berry-Pusey, PhD (COO)

• Leonard S. Marks, MD (CMO)

• Joshua Shubert (CTO)

• Jemima Escamilla, PhD (VP of Business Development and Growth)

• Carolyn Reul (VP of Sales & Marketing)

• Cynthia Weaver (Senior Director of Clinical Affairs)

• Kim Becker (Director Clinical Marketing and Education)

• Cheryl Matter, PhD (Head of Customer Success)

• Emily Malone (Engineering Manager)

• Alan Priester, PhD (Senior Data Scientist)

• Crystal Womack (Quality Manager)

• Jeremy Bong (Staff Cloud Engineer)

• Headquarters: No information is available.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Company Known For: Avenda Health is known for its groundbreaking AI-based prostate cancer decision support platform, Unfold AI, aimed at offering personalized cancer care outcomes.

Products

Unfold AI

• Description: Unfold AI is a decision support platform that leverages artificial intelligence to map prostate cancer in 3D, providing detailed visualization to aid in treatment decisions. This tool is designed to improve and personalize cancer care, enhancing treatment outcomes while preserving quality of life.

• Key Features:

• 3D Visualization: Offers a complete view of cancer's size and extent within the prostate.

• Personalized Cancer Mapping: Uses patient-specific data and deep learning algorithms for accurate cancer mapping.

• FDA Cleared: Unfold AI is the first and only AI-based prostate cancer decision support platform cleared by the FDA.

• Improved Treatment Decisions: Helps in defining treatment margins more accurately, reducing cancer recurrence rates.

Recent Developments

• New Products Launched: No new product launches were reported.

• New Features:

• Enhanced cancer prediction capabilities with AI, leading to better accuracy in estimating cancer margins and improved success rates in prostate cancer treatments.

• New Partnerships:

• Integration with PrecisionPoint® to redefine patient outcomes in the urology domain (October 23, 2023).

Key Milestones and Achievements

• FDA Clearance:

• May 2021: Granted Breakthrough Device Designation by FDA.

• Nov 2022: FDA clearance for AI-based decision support.

• Validation and Recognition:

• Aug 2023: SOC2 compliant, ensuring data security.

• Aug 2023: Study by Stanford validating the effectiveness of Unfold AI.

• Oct 23, 2023: Integration with PrecisionPoint in Urology practice.

Research and Publications

• Extracapsular Extension Risk Assessment Using AI: Published in August 2024.

• Tumor Size Estimation via AI Maps: Detailed in May 2024 publications.

• A Novel Metric for Focal Therapy Candidates: Released in May 2024.

Notable Research and Findings

• AI Superiority in Detection:

• Unfold AI outperformed traditional radiologist evaluations with a 97% sensitivity rate in detecting cancer compared to 37% from traditional methods.

• July 2024: Studies indicate AI detects prostate cancer with 25% greater accuracy than doctors.

Summary

Avenda Health, with its proprietary AI platform Unfold AI, is pioneering changes in prostate cancer management by offering personalized, data-driven insights for better treatment decisions. Through continuous innovation, partnerships, and research validation, the company maintains its commitment to advancing cancer care standards while preserving patient quality of life.